Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?-Reference-Cited by-同舟云学术

Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?

Author:

Herbild Louise¹,Andersen Stig E.²,Werge Thomas³,Rasmussen Henrik B.³,Jürgens Gesche²

Affiliation:

1. Amgros I/S; Copenhagen; Denmark

2. Department of Clinical Pharmacology; Bispebjerg University Hospital; Copenhagen; Denmark

3. Research Institute of Biological Psychiatry; Mental Health Centre Sct. Hans; Copenhagen University Hospital; Roskilde; Denmark

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

Reference24 articles.

4. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders;Serretti;World J Biol Psychiatry,2011

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Polypharmacy and precision medicine;Cambridge Prisms: Precision Medicine;2023